Chemotherapy for Upper Tract Urothelial Carcinoma
Author Information
Author(s): P. H. O'Donnell, W. M. Stadler
Primary Institution: University of Chicago
Hypothesis
Can perioperative chemotherapy reduce the risk of recurrence in patients with locally advanced upper tract urothelial carcinoma?
Conclusion
Neoadjuvant cisplatin-based chemotherapy is recommended as the standard of care for patients with locally advanced upper tract urothelial cancer.
Supporting Evidence
- Locally advanced upper tract urothelial carcinoma has a poor prognosis.
- Surgery is the only potentially curable treatment, but recurrences are common.
- Neoadjuvant chemotherapy has shown survival advantages in bladder cancer.
Takeaway
Doctors think giving chemotherapy before surgery can help people with a type of kidney cancer called upper tract urothelial carcinoma live longer and have fewer problems after surgery.
Methodology
The article reviews existing literature and clinical practices regarding chemotherapy in upper tract urothelial carcinoma.
Potential Biases
Potential biases may arise from the historical difficulties in accruing patients for clinical trials.
Limitations
There is a lack of direct clinical data and trials specifically for upper tract urothelial carcinoma.
Participant Demographics
The article discusses patients with locally advanced upper tract urothelial carcinoma, but specific demographics are not provided.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website